Arpc1b gene is a candidate prediction marker for choroidal malignant melanomas sensitive to radiotherapy

Investigative Ophthalmology and Visual Science

Volumn 47, Issue 6, 2006, Pages 2300-2304

  Kumagai, Ken ^a   Nimura, Yoshinori ^a   Mizota, Atsushi ^b   Miyahara, Nobuyuki ^c   Aoki, Mizuho ^c   Furusawa, Yoshiya ^c   Takiguchi, Masaki ^a   Yamamoto, Shuichi ^a   Seki, Naohiko ^a  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b JUNTENDO UNIVERSITY URAYASU HOSPITAL   (Japan)

^c NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ARPC1B GENE; ARTICLE; CANCER CELL; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHOROID MELANOMA; COLONY FORMING UNIT; COMPARATIVE STUDY; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; MARKER GENE; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RADIOSENSITIVITY; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION; TREATMENT OUTCOME; UPREGULATION; CELL CULTURE; CELL SURVIVAL; CHEMISTRY; CHOROID TUMOR; DNA MICROARRAY; GENE EXPRESSION REGULATION; GENETIC MARKER; GENETICS; MELANOMA; RADIATION DOSE; RADIATION EXPOSURE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ACTIN RELATED PROTEIN 2-3 COMPLEX; ARPC1B PROTEIN, HUMAN; PRIMER DNA; TUMOR PROTEIN;

ACTIN-RELATED PROTEIN 2-3 COMPLEX; CELL SURVIVAL; CHOROID NEOPLASMS; DNA PRIMERS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC MARKERS; HUMANS; MELANOMA; NEOPLASM PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RADIATION TOLERANCE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR CELLS, CULTURED;

EID: 33745638214     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.05-0810     Document Type: Article

References (24)

1. Scotto J, Fraumeni JF Jr, Lee JA. Melanomas of the eye and other noncutaneous sites: epidemiologic aspects. J Natl Cancer Inst. 1976;56:489-491.
2. Ganley JP, Comstock GW. Benign nevi and malignant melanomas of the choroid. Am J Ophthalmol. 1973;76:19-25.
3. Robertson DM. Changing concepts in the management of choroidal melanoma. Am J Ophthalmol. 2003;136:161-170.
4. Collaborative Ocular Melanoma Study Group. The Collaborative Ocular Melanoma Study Group (COMS) randomized trial of preenucleation radiation of large choroidal melanoma, II: initial mortality findings. COMS report no. 10. Am J Ophthalmol. 1998;125:779-796.
5. Jampol LM, Moy CS, Murray TG , et al. The COMS randomized trial of I-125 episcleral plaque for brachytherapy of choroidal melanoma. Am J Ophthalmol. 2000;129:199-204.
6. Gragoudas E, Gostein M, Verhey L, et al. Proton beam irradiation of uveal melanomas: results of a 5 1?2-year study. Arch Ophthalmol. 1982;100:928-934.
7. Char DH, Quivey JM, Castro JR, Kroll S, Phillips T. Helium ions versus iodine-125 brachytherapy in the management of uveal melanoma: a prospective, randomized, dynamically balanced trial. Ophthalmology. 1993;100:1547-1554.
8. Olson JA Jr. Application of microarray profiling to clinical trials in cancer. Surgery. 2004;136:519-523.
9. Clarke PA, te Poele R, Wooster R, Workman P. Gene expression microarray analysis in cancer biology, pharmacology, and drug development: progress and potential. Biochem Pharmacol. 2001;62:1311-1336.
10. De Waard-Siebinga I, Blom DJ, Griffioen M, et al. Establishment and characterization of an uveal-melanoma cell line. Int J Cancer. 1995;62:155-161.
11. Luyten GP, Naus NC, Mooy CM, et al. Establishment and characterization of primary and metastatic uveal melanoma cell lines. Int J Cancer. 1996;66:380-387.
12. Kann-Mitchell J, Mitchell MS, Rao N, Liggett PE. Characterization of uveal melanoma cell lines that grow as xenografts in rabbit eyes. Invest Ophthalmol Vis Sci. 1989;30:829-834.
13. Allen JW, Richardson JD, Edwards MJ. Squamous cell carcinoma of the esophagus: a review and update. Surg Oncol. 1997;6:193-200.
14. Chua YJ, Steer C, Yip D. Recent advances in management of small-cell lung cancer. Cancer Treat Rev. 2004;30:521-543.
15. Koshy M, Esiashvilli N, Landry JC, Thomas CR Jr, Matthews RH. Multiple management modalities in esophageal cancer: combined modality management approaches. Oncologist. 2004;9:147-159.
16. Wakeford R. The cancer epidemiology of radiation. Oncogene. 2004;23:6404-6428.
17. Karran P. DNA double strand break repair in mammalian cells. Curr Opin Genet Dev. 2000;10:144-150.
18. Mullins RD, Heuser JA, Pollard TD. The interaction of Arp2/3 complex with actin: nucleation, high affinity pointed end capping, and formation of branching networks of filaments. Proc Natl Acad Sci USA. 1998;95:6181-6186.
19. Condeelis JS, Wyckoff JB, Bailly M, et al. Lamellipodia in invasion. Semin Cancer Biol. 2001;11:119-128.
20. Machesky LM, Reeves E, Wientjes F, et al. Mammalian actin-related protein 2/3 complex localizes to regions of lamellipodial protrusion and is composed of evolutionarily conserved proteins. Biochem J. 1997;328:105-112.
21. Otomo T, Hishii M, Arai H, Sato K, Sasai K. Microarray analysis of temporal gene responses to ionizing radiation in two glioblastoma cell lines: up-regulation of DNA repair genes. J Radiat Res (Tokyo). 2004;45:53-60.
22. Fukuda K, Sakakura C, Miyagawa K, et al. Differential gene expression profiles of radioresistant oesophageal cancer cell lines established by continuous fractionated irradiation. Br J Cancer. 2004;91:1543-1550.
23. Kitahara O, Katagiri T, Tsunoda T, Harima Y, Nakamura Y. Classification of sensitivity or resistance of cervical cancers to ionizing radiation according to expression profiles of 62 genes selected by cDNA microarray analysis. Neoplasia. 2002;4:295-303.
24. Kaneda A, Kaminishi M, Sugimura T, Ushijima T. Decreased expression of the seven ARP2/3 complex genes in human gastric cancers. Cancer Lett. 2004;212:203-210.